Furthermore, although c-MET-targeted therapies have shown promising results in other cancers, particularly non-small cell lung cancer (40), there remains a paucity of clinical trials and data on c-MET inhibitors in ESCC. This evidence concerns the gene MET and esophageal squamous cell carcinoma.